TScan Therapeutics Inc
NASDAQ:TCRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
TScan Therapeutics Inc
NASDAQ:TCRX
|
US |
|
N
|
Novo Nordisk A/S
XBER:NOVA
|
DK |
|
A
|
Ameresco Inc
F:4AM
|
US |
|
Emera Inc
TSX:EMA
|
CA |
|
Yangarra Resources Ltd
TSX:YGR
|
CA |
|
Grindwell Norton Ltd
NSE:GRINDWELL
|
IN |
|
T
|
Tilray Brands Inc
TSX:TLRY
|
US |
|
G
|
Global Tax Free Co Ltd
KOSDAQ:204620
|
KR |
|
TuSimple Holdings Inc
OTC:TSPH
|
US |
|
NeoMedia Technologies Inc
OTC:NEOM
|
US |
Wall Street
Price Targets
TCRX Price Targets Summary
TScan Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for TCRX is 7.14 USD with a low forecast of 4.04 USD and a high forecast of 12.6 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is TCRX's stock price target?
Price Target
7.14
USD
According to Wall Street analysts, the average 1-year price target for TCRX is 7.14 USD with a low forecast of 4.04 USD and a high forecast of 12.6 USD.
What is TScan Therapeutics Inc's Revenue forecast?
Projected CAGR
38%
For the last 5 years the compound annual growth rate for TScan Therapeutics Inc's revenue is 57%. The projected CAGR for the next 3 years is 38%.